Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans his Department has to help increase the UK’s covid-19 vaccine manufacturing capacity to meet future needs for that vaccine.

The Government has invested over £300 million to secure and scaleup the UK’s manufacturing capabilities to be able to respond to the pandemic, including:

a) Facilities that have come online:

• £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;
• £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire;
• £65.5 million for the early manufacture of the University of Oxford / AstraZeneca vaccine; and
• Funding for fill and finish capability through a contract with Wockhardt in Wrexham, North Wales, which is currently providing fill and finish capabilities to the University of Oxford / AstraZeneca vaccine.

b) Facilities that will come online later this year, to help provide longer term UK capacity:

• £93 million to accelerate the completion and expanded role of the Vaccines Manufacturing Innovation Centre in Oxfordshire; and
• £127 million for the Cell and Gene Therapy Catapult in Braintree, Essex.

In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.